DexCom, Inc. $DXCM Shares Newly Purchased by Radnor Capital Management LLC

Radnor Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 12,910 shares of the medical device company’s stock, valued at approximately $1,114,000.

A number of other institutional investors have also made changes to their positions in DXCM. Signaturefd LLC boosted its stake in DexCom by 7.5% during the 3rd quarter. Signaturefd LLC now owns 5,673 shares of the medical device company’s stock valued at $489,000 after purchasing an additional 397 shares during the period. Simplicity Wealth LLC grew its holdings in DexCom by 5.4% in the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock valued at $273,000 after buying an additional 162 shares during the last quarter. Gibbs Wealth Management increased its position in DexCom by 147.7% in the 3rd quarter. Gibbs Wealth Management now owns 9,084 shares of the medical device company’s stock worth $784,000 after buying an additional 5,417 shares during the period. Wedbush Securities Inc. increased its position in DexCom by 2.6% in the 3rd quarter. Wedbush Securities Inc. now owns 15,286 shares of the medical device company’s stock worth $1,319,000 after buying an additional 383 shares during the period. Finally, Fifth Third Wealth Advisors LLC increased its position in DexCom by 2.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock worth $475,000 after buying an additional 150 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research analyst reports. Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. Wells Fargo & Company raised their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Weiss Ratings upgraded shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Buy” and a consensus target price of $92.43.

DexCom Stock Down 0.5%

NASDAQ DXCM opened at $77.94 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock has a market cap of $29.41 billion, a PE ratio of 30.81, a PEG ratio of 1.31 and a beta of 1.48. The firm has a 50-day simple moving average of $86.79 and a 200 day simple moving average of $76.54. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the company posted $0.48 earnings per share. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Insider Buying and Selling

In other news, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director owned 29,293 shares of the company’s stock, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 24,257 shares of company stock worth $2,049,173. 0.28% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.